# Puma Biotechnology (PBYI) — Earnings

PBYI · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/pbyi/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.16 |
| EPS estimate | $0.04 |
| EPS surprise | +300.00% |
| Revenue surprise | +0.00% |
| Revenue | $56.5M |
| Revenue estimate | $56.5M |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1401667/000143774926026311/pbyi20260630_10q.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/8fdee8ff-0dbe-ccec-6e25-cf0e29d3d74f.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 6, 2026 | $0.04 | $0.16 | 300.00% | $56.5M | $56.5M |
| Q1 2026 | May 7, 2026 | −$0.17 | −$0.07 | 58.82% | $42.0M | $44.8M |
| Q4 2025 | Feb 26, 2026 | $0.19 | $0.26 | 36.84% | $68.6M | $59.9M |
| Q3 2025 | Nov 6, 2025 | $0.05 | $0.17 | 277.78% | $51.0M | $51.9M |
| Q2 2025 | Aug 7, 2025 | $0.09 | $0.12 | 41.18% | $52.0M | $49.2M |
| Q1 2025 | May 8, 2025 | −$0.02 | $0.06 | 400.00% | $44.5M | $43.1M |
| Q4 2024 | Feb 27, 2025 | $0.09 | $0.39 | 349.83% | $52.5M | $59.1M |
| Q3 2024 | Nov 7, 2024 | $0.33 | $0.41 | 23.01% | $70.7M | $80.5M |
| Q2 2024 | Aug 1, 2024 | −$0.13 | −$0.09 | 30.77% | $44.7M | $44.4M |
| Q1 2024 | May 2, 2024 | −$0.22 | −$0.10 | 53.85% | $41.0M | $43.8M |
| Q4 2023 | Feb 29, 2024 | $0.30 | $0.26 | -13.33% | $73.5M | $72.2M |
| Q3 2023 | Nov 2, 2023 | $0.08 | $0.12 | 56.45% | $58.0M | $56.1M |
| Q2 2023 | Aug 3, 2023 | $0.01 | $0.05 | 400.00% | $51.7M | $54.6M |
| Q1 2023 | May 4, 2023 | −$0.08 | $0.03 | 140.00% | $49.6M | $52.8M |
| Q4 2022 | Mar 2, 2023 | $0.05 | −$0.12 | -366.67% | $57.1M | $65.7M |
| Q3 2022 | Nov 3, 2022 | −$0.07 | −$0.01 | 86.32% | $50.5M | $57.1M |
| Q2 2022 | Aug 4, 2022 | $0.01 | $0.21 | 1958.82% | $52.6M | $59.5M |
| Q1 2022 | May 5, 2022 | −$0.17 | −$0.08 | 51.81% | $45.1M | $45.7M |
| Q4 2021 | Mar 3, 2022 | −$0.09 | $0.10 | 214.03% | $47.2M | $55.4M |
| Q3 2021 | Nov 4, 2021 | −$0.31 | −$1.09 | -249.36% | $53.3M | $46.2M |

## Frequently Asked Questions

### When did Puma Biotechnology (PBYI) last report earnings?

Puma Biotechnology last reported on Aug 6, 2026, covering fiscal Q2 2026.

### Did PBYI beat earnings estimates?

Yes. Puma Biotechnology reported EPS of $0.16 for Q2 2026 against a $0.04 estimate — a 300.00% beat.

### How much revenue did PBYI report last quarter?

Puma Biotechnology reported $56.5M in revenue for Q2 2026, against a consensus estimate of $56.5M.

## Similar Stocks

- [ADMA](https://www.lighthorse.io/tickers/adma) — ADMA Biologics Inc - Common Stock
- [CTMX](https://www.lighthorse.io/tickers/ctmx) — CytomX Therapeutics, Inc. - Common Stock
- [TRDA](https://www.lighthorse.io/tickers/trda) — Entrada Therapeutics, Inc. - Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).